|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
|
|---|---|---|
| Net revenues | ||
| Cost of revenues | ||
| Gross profit | ||
| Sales and marketing expenses | ||
| General and administrative expenses | ||
| Research and development expenses | ||
| Reversal of (provision for) credit losses | ||
| Total operating expenses | ||
| Operating income (loss) | ||
| Other income (expenses): | ||
| Other income | ||
| Other expenses | ||
| Interest income | ||
| Interest expense | ||
| Unrealized gains on short-term investments | ||
| Unrealized foreign exchange gain (loss) | ||
| Government subsidy | ||
| Other expenses (income) | ||
| Total other expenses, net | ||
| Income (loss) before income taxes | ||
| Income tax expenses | ||
| Net income (loss) | ||
| Net (income) loss attributable to noncontrolling interests | ||
| Other comprehensive income (loss) | ||
| Foreign currency translation adjustment | ||
| Total comprehensive income (loss) | ||
| Total comprehensive (income) loss attributable to non-controlling interest | ||
| Total comprehensive income (loss) attributable to the Zhengye Biotechnology Holding Limited’s shareholders | ||
| Earnings (loss) per share: | ||
| Basic – ordinary shares (in Dollars per share and Yuan Renminbi per share) | ||
| Class A ordinary shares | ||
| Class B ordinary shares | ||
| Total basic – ordinary shares (in Dollars per share and Yuan Renminbi per share) | ||
| Diluted – ordinary shares (in Dollars per share and Yuan Renminbi per share) | ||
| Class A ordinary shares | ||
| Class B ordinary shares | ||
| Total diluted – ordinary shares (in Dollars per share and Yuan Renminbi per share) | ||
| Weighted average shares outstanding used in calculating basic and diluted earnings per share: | ||
| Ordinary shares – basic (in Shares) | ||
| Class A ordinary shares | ||
| Class B ordinary shares | ||
| Total ordinary shares – basic (in Shares) | ||
| Ordinary shares – diluted (in Shares) | ||
| Class A ordinary shares | ||
| Class B ordinary shares | ||
| Total ordinary shares – diluted (in Shares) | ||
| Net income (loss) attributable to the Zhengye Biotechnology Holding Limited’s shareholders |
Loading...